ProQR Therapeutics was founded in 2012 in Leiden, in the Netherlands. It is a publicly traded (NASDAQ: PRQR) biopharmaceutical company engaged in the development of novel therapeutics. ProQR is focused on the development of innovative ribonucleic acid (RNA) therapies for rare, severe genetic diseases, including cystic fibrosis, inherited blindness disorders and debilitating skin diseases.